2, 3-Dimercaptosuccinic Acid-Modified Iron Oxide Clusters for Magnetic Resonance Imaging
Journal of Pharmaceutical Sciences, ISSN: 0022-3549, Vol: 103, Issue: 12, Page: 4030-4037
2014
- 5Citations
- 15Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations5
- Citation Indexes5
- CrossRef4
- Captures15
- Readers15
- 15
Article Description
Over the last decade, various magnetic nanomaterials have been developed as magnetic resonance imaging (MRI) contrast agents; the greatest challenges encountered for clinical application have been insufficient stability. In this paper, a lyophilization method for 2, 3-dimercaptosuccinic acid-modified iron oxide (γ-Fe 2 O 3 @DMSA) nanoparticles was developed to simultaneously overcome two disadvantages; these include insufficient stability and low-magnetic response. After lyophilization, the clusters of γ-Fe 2 O 3 @DMSA with the size of 156.7 ± 15.3 nm were formed, and the stability of the lyophilized powder (γ-Fe 2 O 3 @DMSA-LP) increased up to over 3 years. It was also found that rehydrated γ-Fe 2 O 3 @DMSA-LP could be ingested by RAW264.7 cells in very large quantities. Results of pharmacokinetics and biodistribution studies in vivo indicated that γ-Fe 2 O 3 @DMSA-LP is a promising liver-targeted material. Furthermore, it also exhibited higher MRI efficiency and longer imaging time in the liver than the well-known product Feridex®. Moreover, results of vascular irritation and long-term toxicity experiments demonstrated γ-Fe 2 O 3 @DMSA-LP could be a nontoxic, biocompatible contrast agent in vivo. Therefore, the proposed γ-Fe 2 O 3 @DMSA-LP can be used as a potential MRI contrast agent in clinic for hepatic diseases. © 2014 Wiley Periodicals, Inc. and the American Pharmacists Association.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0022354915302999; http://dx.doi.org/10.1002/jps.24209; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84914810814&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/25335461; https://linkinghub.elsevier.com/retrieve/pii/S0022354915302999; https://dx.doi.org/10.1002/jps.24209
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know